D. Boral Capital Reaffirms Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $3.00 price objective on the stock.

Several other research firms have also weighed in on VNRX. Maxim Group lowered shares of VolitionRx from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. HC Wainwright reduced their price target on VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, VolitionRx currently has a consensus rating of “Buy” and an average target price of $2.50.

VolitionRx Trading Up 8.4%

NYSE:VNRX opened at $0.32 on Wednesday. The stock has a market capitalization of $39.04 million, a PE ratio of -0.88 and a beta of 1.23. VolitionRx has a 1-year low of $0.22 and a 1-year high of $0.94. The firm has a fifty day simple moving average of $0.29 and a 200 day simple moving average of $0.49.

Institutional Trading of VolitionRx

Several hedge funds and other institutional investors have recently modified their holdings of VNRX. Virtu Financial LLC acquired a new position in VolitionRx in the 3rd quarter valued at about $28,000. Blair William & Co. IL acquired a new stake in VolitionRx during the second quarter worth approximately $30,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx during the second quarter worth approximately $52,000. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of VolitionRx by 15.6% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after acquiring an additional 31,300 shares during the period. Finally, Citadel Advisors LLC grew its position in shares of VolitionRx by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.